Zelavespib (PU-H71)|CAS 873436-91-0|DC Chemicals

Cas No.:	873436-91-0
Chemical Name:	6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine
Synonyms:	6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine;PU-H71;8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-ylamino)propyl]purin-6-amine;PU H71;PU-?H 71;PU-H71 Trifluoroacetic Acid;2fwz;PU-H71,d6;UNII-06IVK87M04;6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine (ACI);PU-H 71;Zelavespib;8-((6-Iodobenzo(d)(1,3)dioxol-5-yl)thio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine;BDBM50180302;SB17115;CHEMBL200102;SW220214-1;AC-33112;HY-11038;BRD-K36529613-001-01-8;9H-Purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-;8-((6-iodo-2H-1,3-benzodioxol-5-yl)sulfanyl)-9-(3-((propan-2-yl)amino)propyl)-9H-purin-6-amine;Hsp90 Inhibitor PU-H71;H71;8-[(6-Iodo-1,3-Benzodioxol-5-Yl)thio]-9-[3-(Isopropylamino)propyl]-9h-Purin-6-Amine;GLXC-02874;BS-17694;NS00070975;J-690375;SUPVGFZUWFMATN-UHFFFAOYSA-N;DB12638;06IVK87M04;8-(6-iodo-benzo(1,3)dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)adenine;DTXCID20158779;PUH71;PU-H-71;SCHEMBL1857579;NSC 750424-d6;8-[(6-IODO-2H-1,3-BENZODIOXOL-5-YL)SULFANYL]-9-[3-(ISOPROPYLAMINO)PROPYL]PURIN-6-AMINE;ZELAVESPIB [INN];NSC752199;PUH-71;873436-91-0;EX-A315;8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)adenine;NCGC00371072-06;BCP03616;CAS# 873436-91-0;8-(6-Iodobenzo[d][1,3]dioxol-5-ylthio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine;1-{2-[2-(2-Fluoroethyl)-2H-tetrazol-5-yl]ethyl}-3-{5-[3-fluoro-4-(methylsulfonyl)phenyl]-4-methyl-1,3-thiazol-2-yl}urea;NSC-752199;HMS3653N04;AKOS024457431;NSC 750424;BCP0726000178;s8039;8-[(6-iodo-2H-1,3-benzodioxol-5-yl)sulfanyl]-9-{3-[(propan-2-yl)amino]propyl}-9H-purin-6-amine;BRD-K36529613-001-02-6;8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-{3-[(1-methylethyl)amino]propyl}-9H-purin-6-amine;DA-41005;PU-H71, d6;DTXSID20236288;8-(6-Iodo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropyl-aminopropyl-d6)adenine (PU-H71-d6);CS-0546;CCG-269784;8-((6-Iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine;CAS#873436-91-0;Q27236209
SMILES:	IC1C(SC2N(CCCNC(C)C)C3C(=C(N)N=CN=3)N=2)=CC2=C(OCO2)C=1
Formula:	C₁₈H₂₁In₆O₂S
M.Wt:	512.367813825607
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.